anti-angiogenesis therapy (Catalyst Biosciences/Pfizer)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-angiogenesis therapy (Catalyst Biosciences/Pfizer)
Drug Alias NameVEGF-2 receptor antagonist (Catalyst/Wyeth)anti-angiogenesis therapy (Catalyst Biosciences/Wyeth)VEGF-2 receptor antagonist (Catalyst/Pfizer)
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionVascular endothelial growth factor receptor 2 modulators
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsChoroidal NeovascularizationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCatalyst Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth LlcCatalyst Biosciences IncPfizer Inc
Active IndicationsN/A
Inactive IndicationsChoroidal NeovascularizationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A